Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress - On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position...

Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress - Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - -...

Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress - Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn’s disease (CD) - - Phase 1a trial...

Prometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate Update -PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn’s Disease in 3Q 2021- -Launched Prometheus Enroll360™, a global patient recruitment...